Mengting Zhang, Jun Yang, Jing Zhang, Cuiyuan Huang, Haiyin Liu, Peiyue Zhang, Yuhong Zhai, Li Liu, Jian Yang
Leucocyte immunoglobulin-like receptors subfamily B (LILRB) belongs to the type I transmembrane glycoproteins, which is the immunosuppressive receptor. LILRBs are widely expressed in bone marrow cells, hematopoietic stem cells, nerve cells and other body cells. Studies have found that LILRBs receptor can bind to a variety of ligands and has a variety of biological functions such as regulating inflammatory response, immune tolerance and cell differentiation. Inflammatory reaction plays a vital role in resisting microorganisms. The function of inhibitory immune receptors can recognize the signs of infection and promote the function of anti-microbial effect. The inflammatory response must be strictly regulated to prevent excessive inflammation and tissue damage. Therefore, it is of general interest to understand the role of LILRBs in the inflammatory response. Because they can inhibit the anti-microbial response of neutrophils, some human pathogens use these receptors to escape immunity. This article reviews the biological role of LILRBs in the inflammatory response. We focus on the known ligands of LILRBs, their different roles after binding with ligands, and how these receptors help to form neutrophil responses during infection. Recent studies have shown that LILRBs recruit phosphatases through intracellular tyrosine-based immunoreceptor inhibitory motifs to negatively regulate immune activation, thereby transmitting inflammation-related signals, suggesting that LILRBs may be an ideal target for the treatment of inflammatory diseases. Here, we describe in detail the regulation of LILRBs on the inflammatory response, its signal transduction mode in inflammation, and the progress in the treatment of inflammatory diseases, providing a reference for further research.
{"title":"Research progress of B subfamily of leucocyte immunoglobulin-like receptors in inflammation","authors":"Mengting Zhang, Jun Yang, Jing Zhang, Cuiyuan Huang, Haiyin Liu, Peiyue Zhang, Yuhong Zhai, Li Liu, Jian Yang","doi":"10.1111/iji.12618","DOIUrl":"10.1111/iji.12618","url":null,"abstract":"<p>Leucocyte immunoglobulin-like receptors subfamily B (LILRB) belongs to the type I transmembrane glycoproteins, which is the immunosuppressive receptor. LILRBs are widely expressed in bone marrow cells, hematopoietic stem cells, nerve cells and other body cells. Studies have found that LILRBs receptor can bind to a variety of ligands and has a variety of biological functions such as regulating inflammatory response, immune tolerance and cell differentiation. Inflammatory reaction plays a vital role in resisting microorganisms. The function of inhibitory immune receptors can recognize the signs of infection and promote the function of anti-microbial effect. The inflammatory response must be strictly regulated to prevent excessive inflammation and tissue damage. Therefore, it is of general interest to understand the role of LILRBs in the inflammatory response. Because they can inhibit the anti-microbial response of neutrophils, some human pathogens use these receptors to escape immunity. This article reviews the biological role of LILRBs in the inflammatory response. We focus on the known ligands of LILRBs, their different roles after binding with ligands, and how these receptors help to form neutrophil responses during infection. Recent studies have shown that LILRBs recruit phosphatases through intracellular tyrosine-based immunoreceptor inhibitory motifs to negatively regulate immune activation, thereby transmitting inflammation-related signals, suggesting that LILRBs may be an ideal target for the treatment of inflammatory diseases. Here, we describe in detail the regulation of LILRBs on the inflammatory response, its signal transduction mode in inflammation, and the progress in the treatment of inflammatory diseases, providing a reference for further research.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 3","pages":"107-116"},"PeriodicalIF":2.2,"publicationDate":"2023-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12618","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9478698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Taeko K. Naruse, Makiko Konishi-Takemura, Risa Yanagida, Gaurav Sharma, Madhu Vajpayee, Hiroshi Terunuma, Narinder K. Mehra, Gurvinder Kaur, Akinori Kimura
One of the KIR allele, KIR3DL1*007, was associated with the progression to acquired immunodeficiency syndrome and not with the susceptibility to HIV-1 infection in the Japanese and Indian populations, implying that KIR3DL1*007-positive NK cells might eliminate HIV-infected cells less effectively than NK cells bearing the other KIR3DL1 alleles or KIR3DS1 alleles.
{"title":"Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 gene *007 may modulate disease progression of human immunodeficiency virus-1 infection in the Japanese population","authors":"Taeko K. Naruse, Makiko Konishi-Takemura, Risa Yanagida, Gaurav Sharma, Madhu Vajpayee, Hiroshi Terunuma, Narinder K. Mehra, Gurvinder Kaur, Akinori Kimura","doi":"10.1111/iji.12617","DOIUrl":"10.1111/iji.12617","url":null,"abstract":"<p>One of the KIR allele, <i>KIR3DL1*007</i>, was associated with the progression to acquired immunodeficiency syndrome and not with the susceptibility to HIV-1 infection in the Japanese and Indian populations, implying that <i>KIR3DL1*007</i>-positive NK cells might eliminate HIV-infected cells less effectively than NK cells bearing the other <i>KIR3DL1</i> alleles or <i>KIR3DS1</i> alleles.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"48-52"},"PeriodicalIF":2.2,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9465859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thank you for your comment on the publication ‘Associations between interleukin 17A and 17F polymorphisms and asthma susceptibility: A meta-analysis’ (Lee & Song, 2023). Your suggestion to focus on the effects of unexpected and potentially confounding genetic variations in future research is particularly important in light of the complexity and ongoing nature of the field of genetic research. As you pointed out, asthma is a complex disease with multiple contributing factors, and it is crucial that future research takes a comprehensive approach in order to fully understand the underlying mechanisms of the disease (Toskala & Kennedy, 2015). By focusing on unexpected and potentially confounding genetic variations, we can expand our understanding of the genetic factors associated with asthma susceptibility and identify new therapeutic targets for the treatment of this condition (Friedrich et al., 2022). Your suggestion is particularly important given the rapid advancements in genetic research and the emergence of new technologies that allow for the identification and characterization of genetic variations. By utilizing these technologies, future research can more efficiently identify novel genetic variations that may be associated with asthma susceptibility, as well as better explain the functional implications of these variations. We will take your suggestion into consideration as we continue to advance our understanding of the genetic factors associated with asthma susceptibility. Young Ho Lee
{"title":"IL-17A and IL-17F polymorphisms and asthma risk: A meta-analysis","authors":"Young Ho Lee","doi":"10.1111/iji.12616","DOIUrl":"10.1111/iji.12616","url":null,"abstract":"Thank you for your comment on the publication ‘Associations between interleukin 17A and 17F polymorphisms and asthma susceptibility: A meta-analysis’ (Lee & Song, 2023). Your suggestion to focus on the effects of unexpected and potentially confounding genetic variations in future research is particularly important in light of the complexity and ongoing nature of the field of genetic research. As you pointed out, asthma is a complex disease with multiple contributing factors, and it is crucial that future research takes a comprehensive approach in order to fully understand the underlying mechanisms of the disease (Toskala & Kennedy, 2015). By focusing on unexpected and potentially confounding genetic variations, we can expand our understanding of the genetic factors associated with asthma susceptibility and identify new therapeutic targets for the treatment of this condition (Friedrich et al., 2022). Your suggestion is particularly important given the rapid advancements in genetic research and the emergence of new technologies that allow for the identification and characterization of genetic variations. By utilizing these technologies, future research can more efficiently identify novel genetic variations that may be associated with asthma susceptibility, as well as better explain the functional implications of these variations. We will take your suggestion into consideration as we continue to advance our understanding of the genetic factors associated with asthma susceptibility. Young Ho Lee","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"64"},"PeriodicalIF":2.2,"publicationDate":"2023-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10109216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dear Editor, we would like to share ideas on the publication ‘Associations between interleukin 17A and 17F polymorphisms and asthma susceptibility: A meta-analysis’ (Lee & Song, 2023). Lee and Song looked for publications reporting IL17 polymorphisms in asthma patients and healthy controls using the PubMed/Medline and Embase databases (Lee & Song, 2023). Asthma susceptibility was studied using meta-analyses to examine the relationships between IL17Ars8193036 (−737C/T), rs2275913 (−197G/A), rs3819024 (A/G), rs3748067 (C/T), and rs4711998 (A/G) polymorphisms and (Lee & Song, 2023) IL17F rs763780 (7488A/G). According to Lee and Song, no correlation between this polymorphism and asthma could be established utilizing the allele contrast, dominant, or homozygous contrast models. In this meta-analysis, no proof of a relationship between any other IL17A and IL17F polymorphism and asthma susceptibility was discovered (Lee & Song, 2023). Finally, Lee and Song found that only the CC genotype of the IL17A rs8193036 polymorphism is linked to asthma susceptibility (Lee & Song, 2023). In this study, the impact of a polymorphism is examined. The hereditary factor discussed in this article might or might not have an effect. We both agree that the targeted observation might be related to the investigated underlying genetic component. However, a variety of genetic variants have been connected to the levels of serum folate, cobalamin, and homocysteine. Examples include NLRP3, MAVS, and GSDM gene polymorphisms (Imraish et al., 2022; Xulong et al., 2022). Future research should concentrate on the effects of unexpected, maybe confounding genetic variations. Amnuay Kleebayoon1 VirojWiwanitkit2
{"title":"Interleukin 17A and 17F polymorphisms and asthma susceptibility: Correspondence","authors":"Amnuay Kleebayoon, Viroj Wiwanitkit","doi":"10.1111/iji.12615","DOIUrl":"10.1111/iji.12615","url":null,"abstract":"Dear Editor, we would like to share ideas on the publication ‘Associations between interleukin 17A and 17F polymorphisms and asthma susceptibility: A meta-analysis’ (Lee & Song, 2023). Lee and Song looked for publications reporting IL17 polymorphisms in asthma patients and healthy controls using the PubMed/Medline and Embase databases (Lee & Song, 2023). Asthma susceptibility was studied using meta-analyses to examine the relationships between IL17Ars8193036 (−737C/T), rs2275913 (−197G/A), rs3819024 (A/G), rs3748067 (C/T), and rs4711998 (A/G) polymorphisms and (Lee & Song, 2023) IL17F rs763780 (7488A/G). According to Lee and Song, no correlation between this polymorphism and asthma could be established utilizing the allele contrast, dominant, or homozygous contrast models. In this meta-analysis, no proof of a relationship between any other IL17A and IL17F polymorphism and asthma susceptibility was discovered (Lee & Song, 2023). Finally, Lee and Song found that only the CC genotype of the IL17A rs8193036 polymorphism is linked to asthma susceptibility (Lee & Song, 2023). In this study, the impact of a polymorphism is examined. The hereditary factor discussed in this article might or might not have an effect. We both agree that the targeted observation might be related to the investigated underlying genetic component. However, a variety of genetic variants have been connected to the levels of serum folate, cobalamin, and homocysteine. Examples include NLRP3, MAVS, and GSDM gene polymorphisms (Imraish et al., 2022; Xulong et al., 2022). Future research should concentrate on the effects of unexpected, maybe confounding genetic variations. Amnuay Kleebayoon1 VirojWiwanitkit2","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"63"},"PeriodicalIF":2.2,"publicationDate":"2023-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10109218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kirstine Kløve-Mogensen, Rudi Steffensen, Tania Nicole Masmas, Andreas Glenthøj, Christina Friis Jensen, Thure Mors Haunstrup, Paul Ratcliffe, Petter Höglund, Henrik Hasle, Kaspar René Nielsen
Autoimmune neutropenia (AIN) in early childhood is caused by autoantibodies directed against antigens on the neutrophil membrane and is a frequent cause of neutropenia in children. Association of AIN with Fcγ receptor (FCGR) 3B variants is well described. In this study, we investigate genetic variations in the FCGR locus and copy number variation of FCGR3B. A total of 130 antibody-positive AIN patients, 64 with specific anti-HNA-1a antibodies and 66 with broad-reacting anti-FcγRIIIb antibodies, were genotyped with a multiplex ligation probe assay and compared with healthy controls. Positive findings were confirmed with real-time q-PCR. We determined copy numbers of the FCGR2 and FCGR3 genes and the following SNPs: FCGR2A Q62W (rs201218628), FCGR2A H166R (rs1801274), FCGR2B I232T (rs1050501), FCGR3A V176F (rs396991), haplotypes for FCGR2B/C promoters (rs3219018/rs780467580), FCGR2C STOP/ORF and HNA-1 genotypes in FCGR3B (rs447536, rs448740, rs52820103, rs428888 and rs2290834). Generally, associations were antibody specific, with all associations being representative of the anti-HNA-1a-positive group, while the only association found in the anti-FcγRIIIb group was with the HNA-1 genotype. An increased risk of AIN was observed for patients with one copy of FCGR3B; the HNA genotypes HNA-1a, HNA-1aa or HNA-1aac; the FCGR2A 166H and FCGR2B 232I variations; and no copies of FCGR2B 2B.4. A decreased risk was observed for HNA genotype HNA-1bb; FCGR2A 166R; FCGR2B 232T; and one copy of FCGR2B promoter 2B.4. We conclude that in our Danish cohort, there was a strong association between variation in the FCGR locus and AIN. The findings of different genetic associations between autoantibody groups could indicate the presence of two different disease entities and disease heterogeneity.
{"title":"Genetic variations in low-to-medium-affinity Fcγ receptors and autoimmune neutropenia in early childhood in a Danish cohort","authors":"Kirstine Kløve-Mogensen, Rudi Steffensen, Tania Nicole Masmas, Andreas Glenthøj, Christina Friis Jensen, Thure Mors Haunstrup, Paul Ratcliffe, Petter Höglund, Henrik Hasle, Kaspar René Nielsen","doi":"10.1111/iji.12614","DOIUrl":"10.1111/iji.12614","url":null,"abstract":"<p>Autoimmune neutropenia (AIN) in early childhood is caused by autoantibodies directed against antigens on the neutrophil membrane and is a frequent cause of neutropenia in children. Association of AIN with Fcγ receptor (FCGR) 3B variants is well described. In this study, we investigate genetic variations in the FCGR locus and copy number variation of <i>FCGR3B</i>. A total of 130 antibody-positive AIN patients, 64 with specific anti-HNA-1a antibodies and 66 with broad-reacting anti-FcγRIIIb antibodies, were genotyped with a multiplex ligation probe assay and compared with healthy controls. Positive findings were confirmed with real-time q-PCR. We determined copy numbers of the FCGR2 and FCGR3 genes and the following SNPs: <i>FCGR2A</i> Q62W (rs201218628), <i>FCGR2A</i> H166R (rs1801274), <i>FCGR2B</i> I232T (rs1050501), <i>FCGR3A</i> V176F (rs396991), haplotypes for <i>FCGR2B/C</i> promoters (rs3219018/rs780467580), <i>FCGR2C</i> STOP/ORF and HNA-1 genotypes in <i>FCGR3B</i> (rs447536, rs448740, rs52820103, rs428888 and rs2290834). Generally, associations were antibody specific, with all associations being representative of the anti-HNA-1a-positive group, while the only association found in the anti-FcγRIIIb group was with the HNA-1 genotype. An increased risk of AIN was observed for patients with one copy of <i>FCGR3B</i>; the HNA genotypes HNA-1a, HNA-1aa or HNA-1aac; the <i>FCGR2A</i> 166H and <i>FCGR2B</i> 232I variations; and no copies of <i>FCGR2B</i> 2B.4. A decreased risk was observed for HNA genotype HNA-1bb; <i>FCGR2A</i> 166R; <i>FCGR2B</i> 232T; and one copy of <i>FCGR2B</i> promoter 2B.4. We conclude that in our Danish cohort, there was a strong association between variation in the FCGR locus and AIN. The findings of different genetic associations between autoantibody groups could indicate the presence of two different disease entities and disease heterogeneity.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"65-74"},"PeriodicalIF":2.2,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12614","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jaqueline de Azevêdo Silva, Camilla Albertina Dantas de Lima, Werbson Lima Guaraná, Alexandre Domingues Barbosa, Thiago Sotero Fragoso, Ângela Luzia Branco Pinto Duarte, Sergio Crovella, Paula Sandrin-Garcia
Bone remodeling is marked by bone synthesis and absorption balance, and any altered dynamic in this process leads to osteoporosis (OP). The interaction of hormonal, environmental and genetic factors regulate bone metabolism. Since vitamin D displays a classic role in bone metabolism regulation, acting through vitamin D receptor (VDR), the genetic variants within VDR were the first ones associated with bone density and remodelling. Therefore, we investigated whether three single nucleotide polymorphisms (SNPs) within VDR were associated with OP differential susceptibility and clinical profile from postmenopausal versus healthy women from Northeast Brazil. Genetic association study enrolling 146 postmenopausal osteoporotic women as the patient group and 95 healthy age-matched women as the control group. We assessed three SNPs within VDR (rs11168268, rs1540339 and rs3890733), considering the clinical profile of all patients. Our results showed an association of rs11168268 G/G genotype with higher bone mineral density (BMD) mean for the total hip (A/A = 0.828 ± 0.09; A/G = 0.081 ± 0.13; G/G = 0.876 ± 0.12, p = .039), and the rs3890733 T/T genotype was associated with increased OP risk in patients below 60 years old (odds ratio [OR] = 5.12, 95% confidence interval [CI ]= 1.13–23.27, p = .012). The rs1540339 T/T genotype was associated with protection for individuals with low melanin deposition when compared to the high melanin deposition group (OR = 0.24, 95%CI = 0.06–0.94, p = .029). Additionally, 61% of patients presented deficient vitamin D serum levels. The SNP rs11168268 G/G was associated with a significantly increased mean total hip BMD in patients OP, highlighting this SNP and its relationship with BMD.
{"title":"Vitamin D receptor gene polymorphisms influence on clinical profile and bone mineral density at different skeletal sites in postmenopausal osteoporotic women","authors":"Jaqueline de Azevêdo Silva, Camilla Albertina Dantas de Lima, Werbson Lima Guaraná, Alexandre Domingues Barbosa, Thiago Sotero Fragoso, Ângela Luzia Branco Pinto Duarte, Sergio Crovella, Paula Sandrin-Garcia","doi":"10.1111/iji.12613","DOIUrl":"10.1111/iji.12613","url":null,"abstract":"<p>Bone remodeling is marked by bone synthesis and absorption balance, and any altered dynamic in this process leads to osteoporosis (OP). The interaction of hormonal, environmental and genetic factors regulate bone metabolism. Since vitamin D displays a classic role in bone metabolism regulation, acting through vitamin D receptor (VDR), the genetic variants within <i>VDR</i> were the first ones associated with bone density and remodelling. Therefore, we investigated whether three single nucleotide polymorphisms (SNPs) within <i>VDR</i> were associated with OP differential susceptibility and clinical profile from postmenopausal versus healthy women from Northeast Brazil. Genetic association study enrolling 146 postmenopausal osteoporotic women as the patient group and 95 healthy age-matched women as the control group. We assessed three SNPs within <i>VDR</i> (rs11168268, rs1540339 and rs3890733), considering the clinical profile of all patients. Our results showed an association of rs11168268 G/G genotype with higher bone mineral density (BMD) mean for the total hip (A/A = 0.828 ± 0.09; A/G = 0.081 ± 0.13; G/G = 0.876 ± 0.12, <i>p</i> = .039), and the rs3890733 T/T genotype was associated with increased OP risk in patients below 60 years old (odds ratio [OR] = 5.12, 95% confidence interval [CI ]= 1.13–23.27, <i>p</i> = .012). The rs1540339 T/T genotype was associated with protection for individuals with low melanin deposition when compared to the high melanin deposition group (OR = 0.24, 95%CI = 0.06–0.94, <i>p</i> = .029). Additionally, 61% of patients presented deficient vitamin D serum levels. The SNP rs11168268 G/G was associated with a significantly increased mean total hip BMD in patients OP, highlighting this SNP and its relationship with BMD.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"75-81"},"PeriodicalIF":2.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9104038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Steven G. E. Marsh, for the WHO Nomenclature Committee for Factors of the HLA System
The following sequences have been submitted to the Nomenclature Committee since the July, August and September 2022 nomenclature update (Marsh, 2022) and, following agreed policy, have been assigned official allele designations (Marsh et al., 2010). Full details of all sequences will be published in a forthcoming report. Below are listed the newly assigned sequences (Table 1) and confirmations of previously reported sequences (Table 2). The accession number of each sequence is given and these can be used to retrieve the sequence files from the EMBL, GenBank or DDBJ data libraries. Although accession numbers have been assigned by the data libraries and most sequences are already available, there is still the possibility that an author may not yet have allowed the sequence to be released; in such a case, you will have to contact the submitting author directly. Additional information pertaining to new sequences is often included in the publications describing these alleles; a listing of recent publications that describe new HLA sequences is given in Table 3. In addition, the sequence for the allele A*23:113N was named in error and has been renamed A*24:586N. The name A*23:113N has therefore been deleted. All new and confirmatory sequences should now be submitted directly to theWHONomenclature Committee for Factors of the HLA System via the IPD-IMGT/HLA Database using the sequence submission tool provided (Barker et al., 2023). The IPD-IMGT/HLA Database may be accessed via the World WideWeb at www.ebi.ac.uk/ipd/imgt/ hla.
{"title":"Nomenclature for factors of the HLA system, update October, November and December 2022","authors":"Steven G. E. Marsh, for the WHO Nomenclature Committee for Factors of the HLA System","doi":"10.1111/iji.12612","DOIUrl":"10.1111/iji.12612","url":null,"abstract":"The following sequences have been submitted to the Nomenclature Committee since the July, August and September 2022 nomenclature update (Marsh, 2022) and, following agreed policy, have been assigned official allele designations (Marsh et al., 2010). Full details of all sequences will be published in a forthcoming report. Below are listed the newly assigned sequences (Table 1) and confirmations of previously reported sequences (Table 2). The accession number of each sequence is given and these can be used to retrieve the sequence files from the EMBL, GenBank or DDBJ data libraries. Although accession numbers have been assigned by the data libraries and most sequences are already available, there is still the possibility that an author may not yet have allowed the sequence to be released; in such a case, you will have to contact the submitting author directly. Additional information pertaining to new sequences is often included in the publications describing these alleles; a listing of recent publications that describe new HLA sequences is given in Table 3. In addition, the sequence for the allele A*23:113N was named in error and has been renamed A*24:586N. The name A*23:113N has therefore been deleted. All new and confirmatory sequences should now be submitted directly to theWHONomenclature Committee for Factors of the HLA System via the IPD-IMGT/HLA Database using the sequence submission tool provided (Barker et al., 2023). The IPD-IMGT/HLA Database may be accessed via the World WideWeb at www.ebi.ac.uk/ipd/imgt/ hla.","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"82-106"},"PeriodicalIF":2.2,"publicationDate":"2023-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9732928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Owing to their role in inflammatory reactions and immunological responses as well as their chromosomal location, interleukin (IL) 17A and 17F are regarded as candidate causal genes associated with asthma. The aim of this study was to determine whether IL17 polymorphisms are associated with susceptibility to asthma. We used the PubMed/Medline and Embase databases to search for studies reporting IL17 polymorphisms in patients with asthma and healthy controls. Meta-analyses were conducted to determine the associations between IL17A rs8193036 (−737C/T), rs2275913 (−197G/A), rs3819024 (A/G), rs3748067 (C/T), and rs4711998 (A/G) and IL17F rs763780 (7488A/G), rs2397084 (T/C), rs1889570 (C/T), rs11465553 (G/A), and rs1266828 (T/C) polymorphisms and asthma susceptibility. A total of 20 studies were included in this meta-analysis. Our results revealed the IL17A rs8193036 CC genotype was associated with asthma susceptibility (odds ratio [OR] = 1.490, 95% confidence interval [CI] = 1.027–2.161, p = .036). However, stratification by ethnicity indicated no association between this polymorphism and asthma in European and Asian subjects. Furthermore, no association was found between this polymorphism and asthma using the allele contrast, dominant or homozygous contrast models. No evidence of an association was found between any of the other IL17A and IL17F polymorphisms and asthma susceptibility in this meta-analysis. This meta-analysis showed that, among the studied polymorphisms, only the CC genotype of IL17A rs8193036 is associated with asthma susceptibility.
{"title":"Associations between interleukin 17A and 17F polymorphisms and asthma susceptibility: A meta-analysis","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.1111/iji.12611","DOIUrl":"10.1111/iji.12611","url":null,"abstract":"<p>Owing to their role in inflammatory reactions and immunological responses as well as their chromosomal location, <i>interleukin (IL) 17A</i> and <i>17F</i> are regarded as candidate causal genes associated with asthma. The aim of this study was to determine whether <i>IL17</i> polymorphisms are associated with susceptibility to asthma. We used the PubMed/Medline and Embase databases to search for studies reporting <i>IL17</i> polymorphisms in patients with asthma and healthy controls. Meta-analyses were conducted to determine the associations between <i>IL17A</i> rs8193036 (−737C/T), rs2275913 (−197G/A), rs3819024 (A/G), rs3748067 (C/T), and rs4711998 (A/G) and <i>IL17F</i> rs763780 (7488A/G), rs2397084 (T/C), rs1889570 (C/T), rs11465553 (G/A), and rs1266828 (T/C) polymorphisms and asthma susceptibility. A total of 20 studies were included in this meta-analysis. Our results revealed the <i>IL17A</i> rs8193036 CC genotype was associated with asthma susceptibility (odds ratio [OR] = 1.490, 95% confidence interval [CI] = 1.027–2.161, <i>p</i> = .036). However, stratification by ethnicity indicated no association between this polymorphism and asthma in European and Asian subjects. Furthermore, no association was found between this polymorphism and asthma using the allele contrast, dominant or homozygous contrast models. No evidence of an association was found between any of the other <i>IL17A</i> and <i>IL17F</i> polymorphisms and asthma susceptibility in this meta-analysis. This meta-analysis showed that, among the studied polymorphisms, only the CC genotype of <i>IL17A</i> rs8193036 is associated with asthma susceptibility.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 2","pages":"53-62"},"PeriodicalIF":2.2,"publicationDate":"2023-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9723313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}